Novel approaches to overcome cancer resistance to conventional therapies – serie

Artificial Intelligence in Gastrointestinal Cancers examines the transformative impact of AI technologies on diagnosing and treating gastrointestinal malignancies. This book explores how advanced algorithms, particularly deep learning models, enhance the analysis of medical imaging, including endoscopic, MRI, and CT scans, facilitating earlier and more accurate identification of cancers such as esophageal, stomach, colorectal, and pancreatic cancers. The content covers AI's multifaceted applications, from improving diagnostic accuracy to personalizing treatment strategies based on genomic and clinical data. It discusses how machine learning predicts patient outcomes and optimizes treatment plans while also addressing AI's role in accelerating drug discovery and clinical trials. For an academic audience, this book provides crucial insights into AI's current and future applications in GI oncology. Readers gain a comprehensive understanding of AI diagnostic tools and personalized treatment strategies, equipping researchers and clinicians with the knowledge to leverage these advancements for improved patient care and outcomes in gastrointestinal cancers.Provides a comprehensive overview of how AI algorithms are applied in the early detection and diagnosis of gastrointestinal cancersHighlights the role of machine learning in analyzing large datasets to predict treatment responses and patient outcomesOutlines how AI accelerates the process of drug discovery and optimizes clinical trial design

PROTACs Overcome Resistance to Cancer Therapies explores the transformative potential of proteolysis targeting chimeras (PROTACs) in addressing one of oncology’s greatest challenges: drug resistance. Edited by Dr. Daohong Zhou, this volume brings together leading experts to present the latest advances in targeted protein degradation for cancer treatment. The book covers foundational principles of PROTAC design, mechanisms of action, and their advantages over traditional small molecule inhibitors. It delves into strategies for targeting undruggable proteins, overcoming resistance in various cancer types, and mitigating emerging resistance to PROTACs.Case studies include BCL-xL, KRAS, STAT3, and EGFR-targeting PROTACs, with insights into clinical translation and precision medicine. This resource equips cancer researchers, oncologists, and pharmaceutical scientists with practical guidance and cutting-edge knowledge. It serves as both a reference and a roadmap for developing next-generation therapeutics, making it essential for those advancing cancer drug discovery and translational medicine.Explains the foundational principles of targeted protein degradation and highlights how PROTACs surpass traditional small molecule inhibitors in efficacy and specificityShowcases diverse applications of PROTACs in targeting undruggable proteins and resistant mutations that are supported by case studies and translational research insightsEquips researchers with methodologies for PROTAC design, optimization, and evaluation while also addressing emerging resistance mechanisms and clinical implications

Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance serves as a vital resource in the evolving field of nuclear medicine, highlighting the transformative potential of theranostic strategies that combine targeted diagnostic imaging with precision radionuclide therapies. The content explores the integration of theranostic techniques into treatment paradigms for cancer and other diseases, emphasizing the unique advantages of nuclear medicine therapies, including reduced side effects, improved quality of life, outpatient accessibility, and cost-effectiveness. For an academic audience, this volume equips clinicians and researchers with insights to enhance patient outcomes by effectively integrating these innovative therapies into clinical practice. The book addresses the pressing challenge of treatment resistance in oncology, providing healthcare professionals with a comprehensive understanding of the latest advancements and their applications. By embracing these advancements, healthcare professionals can contribute to personalized medicine and better address treatment resistance in their patients.Provides a thorough examination of theranostic approaches in nuclear medicine, detailing how these strategies integrate targeted diagnostic imaging with precision radionuclide therapies to combat treatment resistanceExplores the most recent advancements in radionuclide therapies, focusing on their practical applications in clinical settingsHighlights the unique advantages of nuclear medicine therapies, equipping healthcare professionals with the knowledge they need to enhance patient outcomes

Molecular Mechanisms of Cancer Resistance: Emerging Technologies and Therapeutic Strategies explores innovative tools and strategies designed to address the critical issue of drug resistance in cancer treatment. This comprehensive volume is tailored for researchers, clinicians, and students, offering insights into the latest advancements and methodologies in the field. The book covers essential topics such as molecular mechanisms of drug resistance, the tumor microenvironment, and emerging technologies like single-cell analysis and computational modeling. Each chapter features contributions from leading experts, providing a multi-dimensional perspective on both foundational concepts and cutting-edge research.By engaging with this book, the academic audience gains access to groundbreaking research and therapeutic strategies that enhance understanding and practice. The knowledge acquired will inspire collaboration and innovation, ultimately contributing to more effective and personalized cancer treatment approaches.Investigates groundbreaking research and technologies that address the critical challenge of drug resistance in cancerShowcases a variety of innovative therapeutic strategies and tools, equipping researchers, clinicians, and students with practical approaches to developing effective cancer treatmentsPresents knowledge and perspectives from leading experts in cancer drug resistance, offering readers access to high-level expertise and fostering a deeper understanding of emerging trends and methodologies

Sarcoma Immunology and Immunotherapy offers a timely and comprehensive review of the rapidly evolving field of sarcoma immunology and immunotherapy. This book serves as an essential resource for healthcare professionals, scientists, and patients, providing insights into the immunologic features of sarcoma and the latest immune-based treatments. Focussing on the recent advances, the book discusses the sarcoma microenvironment and the development of innovative immunotherapies tailored for sarcoma patients. Readers will benefit from a thorough overview of existing knowledge, encompassing foundational concepts in sarcoma immunology, a detailed examination of laboratory research, and a complete summary of ongoing immunotherapy trials. This holistic approach ensures a robust understanding of the current landscape in sarcoma research and treatment. By equipping readers with essential background information and comprehensive reviews, this book fosters a deeper understanding of sarcoma immunology and therapeutic strategies. It empowers healthcare professionals and scientists to stay abreast of critical studies, ultimately enhancing patient care and outcomes in this challenging field.Offers sufficient background to help readers understand the fundamental concepts of sarcoma immunology, ensuring a solid grasp of the subjectDelivers a comprehensive overview of laboratory research on sarcoma immunology, highlighting recent discoveries and advancements in the fieldPresents a full overview of sarcoma immunotherapy trials and emerging directions, keeping readers informed about the latest therapeutic developments and clinical applications

Deciphering Cancer Resistance: Mechanisms, Targets, and Emerging Therapies addresses the critical challenge of treatment resistance in oncology. The book provides a comprehensive examination of the cellular, molecular, and genetic mechanisms behind resistance, unveiling insights from cancer biology and genomics that inform novel therapeutic strategies. Sections explore cutting-edge technologies like CAR-T cell therapy, nanotechnology, and artificial intelligence, highlighting their role in discovering new treatment modalities. Readers will find the latest preclinical and clinical data, including newly FDA-approved therapies, demonstrating their potential to improve patient outcomes.For academics, this resource consolidates the latest research and clinical developments, aiding researchers, clinicians, and students in staying updated on advancements. It will also be a great guide for graduate studies and research, offering critical insights into drug development and targeted therapies for professionals in the pharmaceutical and biotechnology sectors, ultimately driving progress in cancer treatment.Provides an in-depth analysis of cellular, molecular, and genetic mechanisms behind cancer treatment resistanceExplores cutting-edge technologies such as CAR-T cell therapy, nanotechnology, and artificial intelligence in addressing resistancePresents the latest preclinical and clinical data, including newly FDA-approved therapies, to enhance patient outcomes

Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized.For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.Combines knowledge from cancer biology, molecular biology, biotechnology, and nanotechnology to provide a comprehensive understanding of chemoresistance and innovative drug delivery systemsShowcases the latest advancements in drug delivery methods, including nanomedicine and biomimetic strategies, emphasizing their potential to enhance therapeutic efficacy and minimize off-target effectsPresents solutions to overcome cancer chemoresistance, equipping researchers, clinicians, and industry professionals with essential knowledge to navigate the evolving landscape of cancer therapeutics

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. The volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. It is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance.By bringing together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes, this resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.Integrates hypoxia, tumor heterogeneity, and immune evasion to provide a unified framework for understanding resistance mechanisms in cancerPresents cutting-edge research and clinical insights from global experts, offering a comprehensive view of tumor microenvironment dynamicsEquips researchers and clinicians with translational strategies to design innovative immunotherapies and improve patient outcomes